UCB
The Real-World Evidence Strategy Lead, Respiratory is responsible for developing and delivering global real-world evidence strategies for respiratory assets. This strategic role involves translating research questions into evidence plans that support clinical development, regulatory decisions, market access, and patient outcomes. The position requires collaboration across multiple internal and external stakeholders to ensure evidence is relevant and timely.
Headquarters
Brussels, Brussels, Belgium
Company Size
5001-10000 employees
Founded
1928
UCB a global biopharmaceutical leader focuses on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for UCB.
UCB didn’t post a salary, so this is our estimate from similar listings.
Director, HEOR Strategy, Global Immunology Pipeline
AbbVie
Head of Global RWE and HEOR Strategy - Immunology (BOS)
City of Winnipeg
Real World Evidence (RWE) Lead - London Hybrid role
biomarin
Director, Respiratory Biologics - Global Real-World Evidence & Health Outcomes
lifelancer
Director, RWE, CMH
Eli Lilly and Company
Head of Global RWE and HEOR Strategy - Immunology (BOS)
City of Pierre, South Dakota